The fibrogenic process and the unleashing of acute-on-chronic liver failure
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Acute-on-chronic liver failure (ACLF) is a life-threatening condition characterized by a rapid deterioration of previously well-compensated chronic liver diseases. One of the main obstacles in ACLF is the lack of knowledge of the pathogenesis and specific broad-spectrum treatments. An excessive systemic inflammatory response has been proposed to explain the pathogenesis of ACLF; this hypothesis involves stellate cells, which are implicated in many liver homeostatic functions that include vitamin A storage, regulation of sinusoidal blood flow, local inflammation, maintenance of the hepatocyte phenotype and extracellular matrix remodeling. However, when there is damage to the liver, these cells are the main target of the inflammatory stimulus, as a result, the secretion of the extracellular matrix is altered. Activated hepatic stellate cells raise the survival of neutrophils by the stimulation of granulocytes colonies and macrophages, which exacerbates liver inflammation and promotes damage to hepatocytes. Elevation of pathogen-associated molecular patterns is related to liver damage by different pathophysiological mechanisms of decompensation, showing ballooning degeneration and cell death with a predominance of cholestatic infection. Moreover, patients with ACLF present a marked elevation of C-reactive protein together with an elevation of the leukocyte count. Chronic liver disease is a complex pathological state with a heterogeneous pathophysiology in which genetic factors of the host and external triggers interact and culminate in hepatic insufficiency. The better understanding of such interactions should lead to a better comprehension of the disease and to the discovery of new treatment targets that will make acute decompensations preventable and even decrease mortality.
Abstract
Acute-on-chronic liver failure (ACLF) is a life-threatening condition characterized by a rapid deterioration of previously well-compensated chronic liver diseases. One of the main obstacles in ACLF is the lack of knowledge of the pathogenesis and specific broad-spectrum treatments. An excessive systemic inflammatory response has been proposed to explain the pathogenesis of ACLF; this hypothesis involves stellate cells, which are implicated in many liver homeostatic functions that include vitamin A storage, regulation of sinusoidal blood flow, local inflammation, maintenance of the hepatocyte phenotype and extracellular matrix remodeling. However, when there is damage to the liver, these cells are the main target of the inflammatory stimulus, as a result, the secretion of the extracellular matrix is altered. Activated hepatic stellate cells raise the survival of neutrophils by the stimulation of granulocytes colonies and macrophages, which exacerbates liver inflammation and promotes damage to hepatocytes. Elevation of pathogen-associated molecular patterns is related to liver damage by different pathophysiological mechanisms of decompensation, showing ballooning degeneration and cell death with a predominance of cholestatic infection. Moreover, patients with ACLF present a marked elevation of C-reactive protein together with an elevation of the leukocyte count. Chronic liver disease is a complex pathological state with a heterogeneous pathophysiology in which genetic factors of the host and external triggers interact and culminate in hepatic insufficiency. The better understanding of such interactions should lead to a better comprehension of the disease and to the discovery of new treatment targets that will make acute decompensations preventable and even decrease mortality.
참고문헌 (50)
- Lim SS, "A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010 : a systematic analysis for the Global Burden of Disease Study 2010", Lancet, 380, pp.2224~2260 (2012)
- Jalan R, "Acute-on-chronic liver failure : pathophysiological basis of therapeutic options", Blood Purif, 20, pp.252~261 (2002)
- Arroyo V, "Acute-on-chronic liver failure : definition, diagnosis, and clinical characteristics", Semin Liver Dis, 36, pp.109~116 (2016)
- Friedman SL, "Mechanisms of hepatic fibrogenesis", Gastroenterology, 134, pp.1655~1669 (2008)
- Friedman SL, "Liver fibrosis -- from bench to bedside", J Hepatol, 38(Suppl 1), pp.S38~S53 (2003)
- Ferrell L, "Liver pathology: cirrhosis, hepatitis, and primary liver tumors. Update and diagnostic problems", Mod Pathol, 13, pp.679~704 (2000)
- Krishnan A, "A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition", Am J Physiol Gastrointest Liver Physiol, 312, pp.G666~G680 (2017)
- Zhou Z, "Neutrophilhepatic stellate cell interactions promote fibrosis in experimental steatohepatitis", Cell Mol Gastroenterol Hepatol, 5, pp.399~413 (2018)
- Qiao H, "NADPH oxidase signaling pathway mediates mesenchymal stem cell-induced inhibition of hepatic stellate cell activation", Stem Cells Int, 2018, pp.1239143~ (2018)
- Qiao QH, "Nonalcoholic fatty liver was associated with asymptomatic gallstones in a Chinese population", Medicine(Baltimore), 96, pp.e7853~ (2017)
- Turco L, "Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis", J Hepatol, 68, pp.949~958 (2018)
- Shetty S, "Lymphocyte recruitment to the liver : molecular insights into the pathogenesis of liver injury and hepatitis", Toxicology, 254, pp.136~146 (2008)
- Wree A, "The inflammasome in liver disease", J Hepatol, 65, pp.1055~1056 (2016)
- Moreau R, "Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis", Gastroenterology, 144, pp.1426~1437.e1-e9 (2013)
- Sarin SK, "Acute-on-chronic liver failure : terminology, mechanisms and management", Nat Rev Gastroenterol Hepatol, 13, pp.131~149 (2016)
- Sarin SK, "Acute-on-chronic liver failure : consensus recommendations of the Asian Pacific Association for the study of the liver(APASL)", Hepatol Int, 3, pp.269~282 (2009)
- Bajaj JS, "Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures", Hepatology, 60, pp.250~256 (2014)
- Arroyo V, "Acute-on-chronic liver failure : a new syndrome that will re-classify cirrhosis", J Hepatol, 62(1 Suppl), pp.S131~S143 (2015)
- Bajaj JS, "Defining acute-on-chronic liver failure: will East and West ever meet?", Gastroenterology, 144, pp.1337~1339 (2013)
- Bernsmeier C, "Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK", Gastroenterology, 148, pp.603~615.e14 (2015)
- Li X, "Patients with HBVrelated acute-on-chronic liver failure have increased concentrations of extracellular histones aggravating cellular damage and systemic inflammation", J Viral Hepat, 24, pp.59~67 (2017)
- Verdelho M, "Acute-on-chronic liver failure : a portuguese single-center reference review", GE Port J Gastroenterol, 25, pp.18~23 (2018)
- Macdonald S, "Cell death markers in patients with cirrhosis and acute decompensation", Hepatology, 67, pp.989~1002 (2018)
- Aravinthan A, "Hepatocyte senescence predicts progression in nonalcohol-related fatty liver disease", J Hepatol, 58, pp.549~556 (2013)
- Wan J, "M2 kupffer cells promote hepatocyte senescence : an IL-6-dependent protective mechanism against alcoholic liver disease", Am J Pathol, 184, pp.1763~1772 (2014)
- Waidmann O, "Cytokeratin 18-based cell death markers indicate severity of liver disease and prognosis of cirrhotic patients", Liver Int, 36, pp.1464~1472 (2016)
- Yu X, "Serum interleukin(IL)-9 and IL-10, but not T-Helper 9(Th9)cells, are associated with survival of patients with acute-on-chronic hepatitis B liver failure", Medicine(Baltimore), 95, pp.e3405~ (2016)
- Kulkarni S, "Acute on chronic liver failure-in-hospital predictors of mortality in ICU", J Clin Exp Hepatol, 8, pp.144~155 (2018)
- Li H, "Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation", J Hepatol, 63, pp.50~59 (2015)
- Sonika U, "Alcohol-related acute-on-chronic liver failure-comparison of various prognostic scores in predicting outcome", Indian J Gastroenterol, 37, pp.50~57 (2018)
- Rincon D, "Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis", Aliment Pharmacol Ther, 25, pp.841~848 (2007)
- Katoonizadeh A, "Early features of acute-on-chronic alcoholic liver failure : a prospective cohort study", Gut, 59, pp.1561~1569 (2010)
- Mookerjee RP, "The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis", J Hepatol, 55, pp.1103~1111 (2011)
- Arroyo V, "Acute-on-chronic liver failure in cirrhosis", Nat Rev Dis Primers, 2, pp.16041~ (2016)
- Solé C, "Characterization of inflammatory response in acute-on-chronic liver failure and relationship with prognosis", Sci Rep, 6, pp.32341~ (2016)
- Ariza X, "Neutrophil gelatinase-associated lipocalin is a biomarker of acute-onchronic liver failure and prognosis in cirrhosis", J Hepatol, 65, pp.57~65 (2016)
- Jiang H, "Association of a singlenucleotide polymorphism within the miR-146a gene with susceptibility for acute-on-chronic hepatitis B liver failure", Immunogenetics, 65, pp.257~263 (2013)
- Deng G, "Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers", Gastroenterology, 134, pp.716~726 (2008)
- Lin TM, "Hepatitis B virus markers in Chinese twins", Anticancer Res, 9, pp.737~741 (1989)
- Lei RX, "Influence of a single nucleotide polymorphism in the P1 promoter of the furin gene on transcription activity and hepatitis B virus infection", Hepatology, 50, pp.763~771 (2009)
- Tan W, "Genome-wide association study identifies HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure", Gut, 67, pp.757~766 (2018)
- Ren X, "Hepatitis B virus genotype and basal core promoter", precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without preexisting liver cirrhosis, 2010, pp.17, 887~895
- Xu Z, "Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease : an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure", J Gastroenterol, 46, pp.391~400 (2011)
- Zang H, "Clinical and virological implications of A1846T and C1913A", G mutations of hepatitis B virus genome in severe liver diseases, 2018, pp.53, 319~328
- Skevaki C, "Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases", Clin Exp Immunol, 180, pp.165~177 (2015)
- Rong Y, "Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure", Inflammation, 36, pp.413~418 (2013)
- Bernsmeier C, "CD14+ CD15-HLA-DR-myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-onchronic liver failure", Gut, 67, pp.1155~1167 (2018)
- Citores MJ, "Toll-like receptor 3 L412F polymorphism may protect against acute graft rejection in adult patients undergoing liver transplantation for hepatitis C-related cirrhosis", Transplant Proc, 43, pp.2224~2226 (2011)
- Lu Y, "MiR-145reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells", Oncol Rep, 29, pp.67~72 (2013)
- Alvarado-Tapias E, "Toll-like receptor 4 polymorphisms and bacterial infections in patients with cirrhosis and ascites", World J Hepatol, 10, pp.124~133 (2018)